Notes: YL-109 is an anticancer agent.{52496} It inhibits the proliferation of MCF-7 and MDA-MB-231 cells (IC50s = 0.0858 and 4.2 µM, respectively), as well as migration and invasion by MDA-MB-231 cells in vitro. It induces expression of carboxyl terminus of Hsp70-interacting protein (CHIP) in MDA-MB-231 cells in an AHR-dependent manner. YL-109 (1 µM) inhibits MDA-MB-231-derived cancer stem cell (CSC) mammosphere formation. In vivo, YL-109 (15 mg/kg) reduces tumor volume and the number of metastases in an MDA-MB-231 mouse xenograft model.